Drug Profile
Ulobetasol lotion - Ortho Dermatologics
Alternative Names: BRYHALI; Halobetasol propionate - Ortho Dermatologics; IDP-122; JEMDELLatest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies; Ortho Dermatologics
- Class Anti-inflammatories; Antiallergics; Antipsoriatics; Corticosteroids; Skin disorder therapies; Small molecules
- Mechanism of Action Phospholipase A2 inhibitors; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Plaque psoriasis
- Registered Dermatitis
Most Recent Events
- 02 Dec 2022 US District Court for the District of New Jersey issued a favorable decision for DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US
- 05 May 2021 Registered for Dermatitis in Canada (Topical)
- 05 May 2021 Registered for Plaque psoriasis in Canada (Topical)